Ablynx
Technologiepark 4
Ghent
Zwijnaarde
9052
Tel: 32-0-9-261-06-32
Fax: 32-0-9-261-06-28
Website: http://www.ablynx.com/
Email: info@ablynx.com
282 articles about Ablynx
-
Ablynx Announces Warrants Exercise and Conversion of Bonds – Jan. 22, 2018
1/22/2018
As a result of these transactions, Ablynx now has a share capital of €140,320,046.59 represented by a total number of 75,065,990 shares, conferring a total number of 75,065,990 voting rights.
-
Ablynx: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") – Jan. 18, 2018
1/18/2018
The notifications contain the following information:
-
Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law") – Jan. 16, 2018
1/16/2018
Van Herk Investments B.V. notified Ablynx that it has crossed the 10% threshold on 12 January 2018 and now holds 7,629,229 voting securites of Ablynx.
-
Ablynx: Publication In Accordance With Article 14 of The Belgian Law Of 2 May 2007 Regarding The Publication of Major Shareholdings (The "Transparency Law") - Jan. 10, 2018
1/10/2018
The company received a notification of shareholdings from Consonance CapMan GP LLC on 5 January 2018.
-
The offers underline Novo Nordisk's interest in expanding beyond diabetes and into the rare diseases market.
-
Will this new buy be enough for Celgene investors?
-
Ablynx Announces Board Changes
1/8/2018
Ablynx today announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board with immediate effect.
-
Ablynx to Present at the 36th Annual J.P. Morgan Healthcare Conference
1/4/2018
Ablynx today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific Standard Time (06:30 p.m. Central European Time).
-
Ablynx Release: Notice in Relation to Waiver of Lock-Up Restriction
12/27/2017
The waiver will take effect on 29 December 2017 and the securities may be sold on or after such date.
-
Ablynx Announces Positive Data From its Japanese Ethno-Bridging Study of Caplacizumab
12/21/2017
Ablynx today announced that the single and multiple dose Phase I study demonstrated comparable PK of caplacizumab in Japanese and Caucasian subjects.
-
Ablynx Reports Additional Clinically Important Benefits of Caplacizumab From Its Phase III Hercules Study in Acquired TTP
12/12/2017
These new data relate to additional pre-specified secondary endpoints and demonstrate that treatment with caplacizumab resulted in a clinically meaningful reduction in the use of PEX and length of stay in the ICU and the hospital.
-
Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following ASH Late-Breaking Data Presentation
12/7/2017
The late-breaking data presentation will include positive topline results from the Phase III HERCULES study of caplacizumab announced on 2 October 2017 together with important data from additional analyses on the use of plasma exchange.
-
Ablynx: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") – Nov. 29, 2017
11/29/2017
Millennium Group Management LLC notified Ablynx that it has crossed downward the lowest threshold on 21 November 2017.
-
Ablynx: Results From the Phase III Hercules Study of Caplacizumab for the Treatment of Acquired TTP Selected For Presentation in the Late-Breaking Abstracts Session at the 2017 ASH Annual Meeting
11/21/2017
Positive topline results from the Phase III HERCULES study, meeting primary and two key secondary endpoints, were announced on 2 October 2017.
-
Ablynx Announces Results for the First Nine Months Of 2017 and A Year-to-Date Business Update
11/16/2017
Revenues of €44.7 million (2016: €68.9 million).
-
Ablynx: Publication in Accordance With Article 14 of The Belgian Law of 2 May 2007 Regarding The Publication of Major Shareholdings (The "Transparency Law") - Nov. 10, 2017
11/10/2017
The company received a notification of shareholdings from Millennium Group Management LLC on 7 November 2017.
-
Ablynx: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") – Nov. 3, 2017
11/3/2017
In a first notification (dated 31 October 2017), Millennium Group Management LLC notified Ablynx that it holds 1,889,639 voting securities of Ablynx.
-
Ablynx Closes on Underwriters' Option to Purchase $30M of Additional Shares in the U.S. Initial Public Offering
10/31/2017
The underwriters exercised their option to purchase additional ADSs, in full, on October 26, 2017.
-
Ablynx Closes $200M IPO in the United States
10/30/2017
The net proceeds are estimated at $182.3 million. -
Ablynx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and End of Stabilization Period
10/27/2017
The exercise of the greenshoe option also marks the end of the stabilization period in relation to the initial U.S. public offering.